Who are Trivalent Inactivated Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qiv, DTacP-IPV combined vaccine (TETRAXIM™), Seasonal Inactivated Influenza Vaccine, GamEvac-Combi (vaccine), Quadrivalent Influenza Vaccine, Seqirus QIV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trivalent-inactivated-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Trivalent Inactivated Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trivalent Inactivated Vaccine (Trivalent Inactivated Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated vaccine. Area: Immunology.

marketed Inactivated vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Trivalent Inactivated Vaccine (Trivalent Inactivated Vaccine) — McMaster University. A trivalent inactivated influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus, providing protection against seasonal flu infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Trivalent Inactivated Vaccine TARGET	Trivalent Inactivated Vaccine	McMaster University	marketed	Inactivated vaccine
Qiv	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3
Seasonal Inactivated Influenza Vaccine	Seasonal Inactivated Influenza Vaccine	Pfizer	marketed	Inactivated vaccine
GamEvac-Combi (vaccine)	GamEvac-Combi (vaccine)	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	marketed	Combination inactivated vaccine
Quadrivalent Influenza Vaccine	Quadrivalent Influenza Vaccine	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Inactivated vaccine	Influenza viruses
Seqirus QIV	Seqirus QIV	Seqirus	phase 3	inactivated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated vaccine class)

Pfizer · 3 drugs in this class
McMaster University · 1 drug in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class
Sinovac Biotech Co., Ltd · 1 drug in this class
St. Petersburg Research Institute of Vaccines and Sera · 1 drug in this class
The University of Hong Kong · 1 drug in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 1 drug in this class
Vac4All · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trivalent Inactivated Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/trivalent-inactivated-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab